Genezen receives growth equity investment from Ampersand Capital Partners

Scroll Down

Genezen, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, vector production, and analytical testing services, today announced a majority investment from Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector. Ampersand’s investment will be used to complete the construction of the company’s 25,000 square foot cGMP-compliant lentiviral vector production facility, which will also offer a full suite of process development and analytical capabilities.

Read the full press release here.

You may also be interested in...

Genezen’s new viral vector process development…

Our new state-of-the-art, cGMP-compliant multi-vector production facility is now open! Our...

Read more

Our Capabilities

Genezen offers contract process development, GMP viral vector production, transduced cell...

Read more

Operations commence at Genezen’s lenti- and…

Genezen, Inc., a cell and gene therapy Contract Development and Manufacturing...

Read more

Genezen Appoints Vice President of Quality…

Genezen Inc., a cell and gene therapy Contract Development and Manufacturing...

Read more